AKT1 and neoplasm: Chen et al. (106) further reported that APS significantly decreased PI3K and Akt expression in EC rats, with tumor inhibition rates of 45.59% (400 mg/kg), 32.35% (200 mg/kg), and 17.65% (100 mg/kg) under different dosing regimens.